Inhibition of ERK signaling is a promising target for many types of tumors, but in GBM, enhanced ERK signaling in response to SPRY2 knockdown blocks intracranial tumor growth through premature onset of DNA replication, increased DNA damage, and impaired proliferation [43,68]. Here, SPRY2 is linked to glioblastoma.